The global Parkinson’s disease treatment market accounted for USD 5.40 billion in 2023 and is expected to reach at USD 19.10 billion by 2034 with a CAGR of 12.17% during the forecast period 2024-2034. Rising elderly population, increase in Parkinson’s Disease (PD) cases, a robust pipeline of therapies aimed at modifying the progression of the disease, surge in healthcare spending, growing research & development efforts, rising number of clinical trials, increasing approval of new treatment options by regulatory bodies, and surge in introduction of innovative therapies by market leaders are some of the key factors boosting the market growth.
Surge in introduction of innovative therapies by market leaders is predicted to boost the market growth during the forecast period. Parkinson’s disease is a progressive neurological disorder characterized by the degeneration of dopaminergic cells in the brain. Common symptoms include tremors, stiffness, slowed movement, and instability in posture. For instance, in January 2024, AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for managing advanced Parkinson's disease characterized by severe motor fluctuations and either hyperkinesia or dyskinesia.
By drug class, carbidopa-levodopa was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the rise in the prescription rates of these medications and increasing approvals from regulatory agencies. Carbidopa and Levodopa, a combination medication, are prescribed for managing symptoms of Parkinson's disease. They are widely regarded as the most potent and frequently prescribed medication for Parkinson's disease as a secondary treatment option. These medications are primarily administered orally, available in various forms such as immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules. For instance, in August 2023, Aspen Neuroscience declared that its Investigational New Drug (IND) application for a novel gene therapy for Parkinson’s Disease, ANPD001, has been approved by the United States Food and Drug Administration (FDA). Additionally, MAO-B Inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities, and increasing development of novel medicines for the treatment of the disease.
By route of administration, oral was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to its convenience for the majority of patients, increasing elderly population, and rise in partnerships among market participants. For instance, in June 2022, Biogen and Alectos Therapeutics have formed a partnership to license and collaborate on the development and commercialization of AL01811, a groundbreaking preclinical selective GBA2 inhibitor. This compound holds promise as a first-of-its-kind oral therapy designed to modify the course of Parkinson’s disease (PD). Additionally, Injection is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on developing innovative intravenous injections to treat various diseases, and rise in approvals for new medications.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023. Parkinson's disease medications such as generic carbidopa-levodopa, pramipexole dihydrochloride, and selegiline hydrochloride are readily accessible in retail pharmacy chains such as Walgreens and Walmart Stores and increase in the introduction of new treatment options by market participants. For instance, in February 2022, Avion Pharmaceuticals, LLC, a division of Alora Pharmaceuticals, has launched DHIVY, the initial and sole fractional tablet of carbidopa/levodopa (CD/LD) meant for division. Additionally, online pharmacy is predicted to grow at the fastest CAGR during the forecast period as these platforms provide comfort, flexibility, and convenience. Online shopping presents a range of discounts, which are advantageous for customers.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players in the region, rising introduction of new PD symptom management products, and growing number of clinical trial procedures. For instance, in January 2022, In Canada, BlueRock Therapeutics provided the initial dose of DA01 (dopaminergic neurons) to individuals with advanced Parkinson's disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in product penetration, increase in the prevalence of Parkinson's disease, and growing number of approvals by regulatory agencies. For instance, in February 2023, UCB, a multinational biopharmaceutical company headquartered in Belgium, has obtained an Import Drug License (IDL) from the China Food and Drug Administration (CFDA). This achievement paves the way for the introduction of NEUPRO®, a transdermal rotigotine patch with continuous 24-hour delivery, to patients in China.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in introduction of innovative therapies by market leaders is predicted to boost the market growth during the forecast period. Parkinson’s disease is a progressive neurological disorder characterized by the degeneration of dopaminergic cells in the brain. Common symptoms include tremors, stiffness, slowed movement, and instability in posture. For instance, in January 2024, AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for managing advanced Parkinson's disease characterized by severe motor fluctuations and either hyperkinesia or dyskinesia.
By drug class, carbidopa-levodopa was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to the rise in the prescription rates of these medications and increasing approvals from regulatory agencies. Carbidopa and Levodopa, a combination medication, are prescribed for managing symptoms of Parkinson's disease. They are widely regarded as the most potent and frequently prescribed medication for Parkinson's disease as a secondary treatment option. These medications are primarily administered orally, available in various forms such as immediate-release tablets, controlled-release tablets, enteral suspension, and extended-release capsules. For instance, in August 2023, Aspen Neuroscience declared that its Investigational New Drug (IND) application for a novel gene therapy for Parkinson’s Disease, ANPD001, has been approved by the United States Food and Drug Administration (FDA). Additionally, MAO-B Inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to the growing research & development activities, and increasing development of novel medicines for the treatment of the disease.
By route of administration, oral was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023 owing to its convenience for the majority of patients, increasing elderly population, and rise in partnerships among market participants. For instance, in June 2022, Biogen and Alectos Therapeutics have formed a partnership to license and collaborate on the development and commercialization of AL01811, a groundbreaking preclinical selective GBA2 inhibitor. This compound holds promise as a first-of-its-kind oral therapy designed to modify the course of Parkinson’s disease (PD). Additionally, Injection is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on developing innovative intravenous injections to treat various diseases, and rise in approvals for new medications.
By distribution channel, retail pharmacy was the highest revenue-grossing segment in the global Parkinson’s disease treatment market in 2023. Parkinson's disease medications such as generic carbidopa-levodopa, pramipexole dihydrochloride, and selegiline hydrochloride are readily accessible in retail pharmacy chains such as Walgreens and Walmart Stores and increase in the introduction of new treatment options by market participants. For instance, in February 2022, Avion Pharmaceuticals, LLC, a division of Alora Pharmaceuticals, has launched DHIVY, the initial and sole fractional tablet of carbidopa/levodopa (CD/LD) meant for division. Additionally, online pharmacy is predicted to grow at the fastest CAGR during the forecast period as these platforms provide comfort, flexibility, and convenience. Online shopping presents a range of discounts, which are advantageous for customers.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of major market players in the region, rising introduction of new PD symptom management products, and growing number of clinical trial procedures. For instance, in January 2022, In Canada, BlueRock Therapeutics provided the initial dose of DA01 (dopaminergic neurons) to individuals with advanced Parkinson's disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rise in product penetration, increase in the prevalence of Parkinson's disease, and growing number of approvals by regulatory agencies. For instance, in February 2023, UCB, a multinational biopharmaceutical company headquartered in Belgium, has obtained an Import Drug License (IDL) from the China Food and Drug Administration (CFDA). This achievement paves the way for the introduction of NEUPRO®, a transdermal rotigotine patch with continuous 24-hour delivery, to patients in China.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Route Of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Parkinson’s Disease Treatment Market Report 2023 - 2034
Parkinson’s Disease Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- COMT inhibitors
- Anticholinergics
- MAO-B Inhibitors
- Dopamine Agonists
- Carbidopa-levodopa
- Others
Parkinson’s Disease Treatment Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Injection
- Transdermal
Parkinson’s Disease Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Parkinson’s Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Parkinson’s Disease Treatment Market: Drug Class Estimates & Trend Analysis
8. Parkinson’s Disease Treatment Market: Route Of Administration Estimates & Trend Analysis
9. Parkinson’s Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Parkinson’s Disease Treatment Market
12. Europe Global Parkinson’s Disease Treatment Market
13. Asia Pacific Global Parkinson’s Disease Treatment Market
14. Latin America Global Parkinson’s Disease Treatment Market
15. MEA Global Parkinson’s Disease Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- Supernus Pharmaceuticals Inc.
- GlaxoSmithKline plc. (GSK)
- Amneal Pharmaceuticals LLC
- Cerevel Therapeutics
- Merck & Co. Inc.
- H. Lundbeck A/S
- Novartis AG
- AbbVie Inc.
